Sonus Pharmaceutical - Worst Pharma Stocks of 2007

Company: Sonus Pharmaceutical
Starting stock price: $6.02
Ending stock price: $0.44
Percent Change: -92.69%

Details: Sonus was delivered a crushing blow in September. A Phase III study of the company's breast cancer therapy, Tocosol Paclitaxel, was found to be less effective and linked to more side effects than Taxol. Bayer Schering terminated it's partnership with Sonus on the drug in October. The company has since enlisted Ferghana Partners to help evaluate the company's "alternative strategies." Sonus has one other cancer drug in development.

Related Articles:
Sonus shares shattered on drug failure. Report
Sonus shares surge as FDA approves Phase III design. Report

Sonus Pharmaceutical - Worst Pharma Stocks of 2007
Read more on

Suggested Articles

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.